Korea's Green Cross Gets Green Light From KFDA To Produce Novartis Adjuvanted A/H1N1 Vaccine
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean vaccine maker Green Cross said it has received the green light from Korea FDA to use Novartis's MF59 adjuvanted A/H1N1 vaccine for production of an A/H1N1 vaccine
You may also be interested in...
Korea's Green Cross Wins Bid To Supply Chicken Pox Vaccine to WHO
SEOUL - South Korea's leading vaccine maker Green Cross has won another round of international bidding to supply the World Health Organization's Pan American Health Organization with its chicken pox vaccine Suduvax worth $10.4 million
Korea's Green Cross Wins Bid To Supply Chicken Pox Vaccine to WHO
SEOUL - South Korea's leading vaccine maker Green Cross has won another round of international bidding to supply the World Health Organization's Pan American Health Organization with its chicken pox vaccine Suduvax worth $10.4 million
Korea FDA Issues Approval To Chong Kun Dang For Future Sales Of Generic Tamiflu
SEOUL - The Korea Food & Drug Administration granted approval to local South Korean Chong Kun Dang Pharmaceutical to sell its generic version of Roche's Tamiflu (oseltamivir) at some point in the future